Intravitreal Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion-A Short-Term Result

眼內注射BEVACIZUMAB治療分枝視網膜靜脈阻塞引起黃斑部水腫之療效－短期結果報告

王元聖(Yuan-Shen Wang) ； 鄭成國(Cheng-Kuo Cheng) ； 彭繼賢(Chi-Hsien Peng) ； 胡朝乾(Chao-Chien Hu) ； 吳慈恩(Tzu-En Wu) ； 林惠真(Hueu-Chen Lin)

《中華民國眼科醫學會雜誌》 48卷3期 (2009/12) Pp. 289-299

https://doi.org/10.30048/ACTASOS.200912.0009

摘要

目的：評估眼內注射bevacizumab治療分枝視網膜靜脈阻塞所造成之黃斑部水腫的安全性與療效。
方法：本篇為回溯性的研究，總共收集了24位因分枝視網膜靜脈阻塞引起黃斑水腫的病人。這些病人皆接受玻璃體內注射2.5毫克bevacizumab的治療，並且根據臨床檢查變化決定是否重覆注射。所有的病人皆追蹤至少3個月以上，主要研究結果則包括最佳矯正視力與中央視網膜厚度的變化。
結果：24位病人的平均年齡為59.8歲（40到75歲）。從產生症狀到接受治療的平均時間為14周（2到56周），平均追蹤時間為10.1個月（3到30個月）。平均視力從治療前的6/50，在最後一次迫蹤時進步到6/16（P值＜0.01）。平均中央視網膜厚度從治療前的439（標準差112）微米，到最後一次追蹤時下降到246（標準差106）微米（P值＜0.01）。在追蹤期間，沒有任何眼壓升高（眼壓＞21毫米汞柱）、視網膜裂孔、玻璃體出血或者眼內炎的併發症發生。
結論：以玻璃體內注射2.5毫克bevacizumab來治療分枝視網膜靜脈引起的黃斑部水腫是有效且安全的選擇。然而，長期的療效及安全性需要進一步的研究。

並列摘要

Purpose: To evaluate the short-term safety and efficacy of intravitreal bevacizumab for the management of macular edema secondary to branch retinal vein occlusion (BRVO).
Methods: A retrospective, non-comparative, consecutive, interventional case series of twenty-four eyes from 24 patients. Patients received repeated intravitreal injections of 2.5 mg bevacizumab. Main outcome measures were best-corrected visual acuity (BCVA) and central retinal thickness (CRT) in a minimum follow-up of 3 months.
Results: Patients presented at a mean age of 59.8 years (range 40-75). Mean duration of symptoms was 14 weeks (range 2-56), and mean follow-up period was 10.1 months (range 3-30). Mean (SD) BCVA at baseline was 1.17 (±0.51) logMAR, improving to 0.62 (±0.53) logMAR at the last follow-up (p＜0.01). Mean (SD) CRT at baseline was 439 (±112)μm, declining to 246 (±106)μm at the last follow-up (p＜0.01). No increased intraocular pressure, retinal tear, vitreous hemorrhage or endophthalmitis was noted during the follow-up period.
Conclusions: Intravitreal injection of 2.5 mg bevacizumb appears to be an effective and safe treatment option for BRVO related macular edema. However, further studies are necessary to evaluate the long-term effect.

並列關鍵字

Bevacizumab ； branch retinal vein occlusion ； macular edema